- Previous Close
13.56 - Open
13.62 - Bid 13.94 x --
- Ask --
- Day's Range
13.62 - 14.20 - 52 Week Range
7.21 - 17.76 - Volume
37,583 - Avg. Volume
73,319 - Market Cap (intraday)
175.832M - Beta (5Y Monthly) -0.25
- PE Ratio (TTM)
2.43 - EPS (TTM)
5.75 - Earnings Date Apr 29, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.00
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
www.santhera.comRecent News: SANN.SW
View MorePerformance Overview: SANN.SW
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SANN.SW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SANN.SW
View MoreValuation Measures
Market Cap
170.79M
Enterprise Value
180.68M
Trailing P/E
2.36
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.31
Price/Book (mrq)
3.55
Enterprise Value/Revenue
1.59
Enterprise Value/EBITDA
2.14
Financial Highlights
Profitability and Income Statement
Profit Margin
55.33%
Return on Assets (ttm)
39.20%
Return on Equity (ttm)
2,374.13%
Revenue (ttm)
113.59M
Net Income Avi to Common (ttm)
62.85M
Diluted EPS (ttm)
5.75
Balance Sheet and Cash Flow
Total Cash (mrq)
16.49M
Total Debt/Equity (mrq)
54.88%
Levered Free Cash Flow (ttm)
-24.75M